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Abstract
Background: Trapped Neutrophil Syndrome (TNS) is a common autosomal recessive neutropenia in Border collie
dogs.
Results: We used a candidate gene approach and linkage analysis to show that the causative gene for TNS is VPS13B.
We chose VPS13B as a candidate because of similarities in clinical signs between TNS and Cohen syndrome, in
human, such as neutropenia and a typical facial dysmorphism. Linkage analysis using microsatellites close to VPS13B
showed positive linkage of the region to TNS. We sequenced each of the 63 exons of VPS13B in affected and control
dogs and found that the causative mutation in Border collies is a 4 bp deletion in exon 19 of the largest transcript
that results in premature truncation of the protein. Cohen syndrome patients present with mental retardation in 99%
of cases, but learning disabilities featured in less than half of TNS affected dogs. It has been implied that loss of the
alternate transcript of VPS13B in the human brain utilising an alternate exon, 28, may cause mental retardation. Mice
cannot be used to test this hypothesis as they do not express the alternate exon. We show that dogs do express
alternate transcripts in the brain utilising an alternate exon homologous to human exon 28.
Conclusion: Dogs can be used as a model organism to explore the function of the alternately spliced transcript of
VPS13B in the brain. TNS in Border collies is the first animal model for Cohen syndrome and can be used to study
the disease aetiology.
Keywords: Trapped Neutrophil Syndrome, Cohen Syndrome, neutropenia, vesicle transport, expression, vesicle
protein sorting 13 B, VPS13B, dog
Background
Dogs consist of over 400 genetically isolated breeds with
considerable morphological and behavioural diversity.
Dog breeds have undergone two major bottlenecks, the
first when they were domesticated from the wolf
~15,000 years ago [1,2], and the second in the last few
hundred years during development of the modern
breeds from a low number of individuals selected for
certain physical or behavioural traits [1,3]. Such heavy
artificial selection results in limited genetic variation
within each breed and many inherited diseases. Inher-
ited diseases in dogs are predominantly recessive, often
resulting from strong inbreeding and usually showing
allelic homogeneity within a breed or group of related
breeds and allelic heterogeneity between less related
breeds [4].
An autosomal recessive neutropenia, known as
Trapped Neutrophil Syndrome (TNS), has been identi-
fied in the Border collie breed. The disease was originally
described in the Australian and New Zealand population
of Border collies and is characterised by a deficiency of
segmented neutrophils in the blood and hyperplasia of
myeloid cells in the bone marrow [5]. Severely affected
pups show abnormal craniofacial development with a
narrowed elongated skull shape described by breeders as
ferret-like. Affected pups are often smaller than their lit-
ter mates and suffer from chronic infections and failure
to thrive resulting from a compromised immune system.
Some show early infections from six weeks of age. For
others the first sign of TNS is a bad reaction to immuni-
sation at 12 weeks, while in a few cases clinical signs are
very mild and not recognised until two or more years of
age [5-7].
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All known TNS affected dogs at the start of this
research could be traced back to a single common
ancestor [7]. This suggested that the disease was the
result of a single mutational event that had been spread
through the population by the champion sire effect.
Champion male show dogs are often used heavily for
breeding to pass on show winning traits. Any detrimen-
tal mutations that a champion male may be carrying
can rapidly spread through a population. When coupled
with inbreeding, recessive diseases can manifest within a
few generations after the champion is used. All affected
dogs are then homozygous and identical-by-descent for
the genomic region surrounding the mutation. We con-
sidered allelic heterogeneity unlikely for TNS given the
recent common ancestor.
A promising approach to identify disease genes is the
candidate gene approach coupled with linkage analysis
using microsatellites from the candidate gene region.
This approach can confirm whether the region is the cor-
rect one even if the mutation is non-coding. We chose
candidate genes in this study based on their role in path-
ways known to be associated with neutrophil maturation
or known to cause neutropenia in humans.
We investigated 10 genes as candidates for TNS, four
of these are known to cause a disease featuring neutrope-
nia and six are linked to neutrophil function. We have
previously excluded six of the genes from this list: che-
mokine (C-X-C motif) receptor 4 (CXCR4), [6]; neutro-
phil elastase (ELANE); adaptor-related protein complex
3, beta 1 subunit (AP3B1); and adaptor-related protein
complex subunits AP3D1, AP3S1 and AP3M1 [7].
One of the other four candidates (Table 1) was the
ligand of CXCR4, chemokine (C-X-C motif) ligand 12
(CXCL12), which may result in a similar phenotype to dis-
ruption of CXCR4. Another candidate was the anti-apop-
totic factor, BCL2-like 1 (BCL2L1), which has been shown
to be down-regulated in cases of neutropenia [8]. We also
investigated interleukin 8 receptor B (CXCR2) as it is able
to attract and activate neutrophils to sites of inflammation
from the blood [9]. We considered Cohen syndrome
(MIM:216550) [10,11] as a model for TNS because of pre-
sence of the clinical signs of neutropenia with hyperplasia
of the bone marrow enriched for the myeloid cell lines
[12] and a typical craniofacial dysmorphism. Cohen syn-
drome is caused by mutations in Vesicle Protein Sorting
13B (VPS13B). We used linkage analysis followed by
sequencing to investigate whether a mutation in one of
these genes is responsible for TNS in Border collies.
Results
We examined the four candidate genes (Table 1) for
linkage to TNS using between one and five microsatel-
lites for each candidate. We eliminated three from being
linked to TNS based on maximum logarithm of odds
(LOD) scores less than minus-two from multipoint link-
age analysis in an eight generation pedigree with seven
to 12 affecteds depending on the analysis (Table 1). We
developed genotyping assays for four microsatellites
from the VPS13B region and named them C13.0390,
C13.0423, C13.0449 and C13.0478 based on chromo-
some number and location in 10’s of kb (Additional file
1, table S1). These microsatellites were highly poly-
morphic with between eight and 14 alleles in a sample
of 72 Border collies (Additional file 1, table S2). We
observed 23 haplotypes involving alleles at these loci
and a large amount of linkage disequilibrium between
alleles (Additional file 1, table S3). Multipoint linkage
analysis for our TNS pedigree, with multiple inbreeding
loops [7], gave significant evidence of linkage with a
maximum LOD score of 8.86 at marker C13.0390
(Additional file 1, figure S1).
We observed strong linkage disequilibrium between
TNS and the microsatellites at VPS13B, with the major-
ity of affected dogs homozygous for a single haplotype
(Additional file 1, figure S2). Variations in the disease
haplotype occurred in three dogs, each at 1 locus only
and likely represent new mutations in the microsatellite
rather than recombinants.
We sequenced each of the 63 exons with at least 100 bp
of flanking intron in two controls, two obligate carriers
and two affecteds. We found 13 coding sites that were
either polymorphic in these dogs or different to the refer-
ence genome (Additional file 1, Table S4, [GenBank:
HM149237, HM149238, HM149239, HM149240,
HM149241, HM149242, HM149243, HM149244,
HM149245, HM149246, HM149247 and HM149248].).
We identified a homozygous four bp deletion in affected
dogs, relative to both Border collie controls and the dog
reference genome. The sequence of the affected allele is a
deletion from bases 4411956 to 4411960 on chromosome
13 (Dog Genome Build 2.1), which is listed as being within
exon 19 of VPS13B (g.4411956_4411960delGTTT, [Gen-
Bank: HM036106]). Obligate carriers (known to have pro-
duced affected offspring) were heterozygous for the four
bp deletion (Additional file 1, figure S3). The deletion
results in frame shift of putative transcript variants 1, 3
and 4 and premature truncation after the 980th amino acid
of the 4019, 3994 and 1427 amino acid VPS13B protein
isoforms, respectively (figure 1).
Table 1 LOD score for linkage analysis using
microsatellites in the region of three candidate genes for
TNS not previously reported
Candidate Name LOD location
BCL2L1 BCL-XL -6.05 Chr 24, 24.1 Mb
CXCL12 stromal cell derived factor 1 -5.90 Chr28, 58.9 Mb
CXCR2 Interleukin 8 receptor -3.34 Chr37, 27.9 Mb
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We sequenced exon 19 in 69 Border collies (six
affected, 10 obligate carriers and 47 of unknown status),
and all affecteds were homozygotes for the GTTT dele-
tion and all obligate carriers were heterozygotes (Table
2). The deletion co-segregated with the TNS phenotype
in all cases. Of the 47 Border collies related to the TNS
pedigree with unknown status, 29 were heterozygous
and 18 were homozygous for the normal sequence. We
designed a PCR assay to detect the deletion based on
the size of the PCR product.
We applied the TNS carrier test to a sample set of
260 Australian Border collies collected before the TNS
research began. These samples can be considered ran-
domly sampled with respect to TNS. We also tested a
set of 80 samples that were collected in Norway to
represent the local Border collie population (phenotype
data was not collected, Table 2). The sample sets gave
allele proportions of 0.07 and 0.08, respectively, for the
DNA Norm 2881 tataactggcttgtttatcagcctcagaaacgaaccagtagacat 2925
aa Norm Y  N  W  L  V  Y  Q  P  Q  K  R  T  S  R  H
DNA Mut   2881 tataactggctt----atcagcctcagaaacgaaccagtagacat 2925
aa Mut Y  N  W  L      I S L R N E P V D I
DNA Norm  2926 atgcagcagcagcctgtcatagctgttcctcttgttacaccaatt 2970
aa Norm        M  Q  Q  Q  P  V  I  A  V  P  L  V  T  P  I 
DNA Mut 2926 atgcagcagcagcctgtcatagctgttcctcttgttacaccaatt 2970
aa Mut C S S S L S *
Figure 1 Partial DNA sequence, sequence electropherogram and amino acid sequence for VPS13B region containing TNS mutation for
normal (Norm) and mutant (Mut) genomic sequence (above) with translation (below). Underlined aa represent expected aa after the
frameshift due to deletion, stop codon represented by *. Number on DNA sequence represents expected location on cDNA of isoform variant 1
Table 2 Genotyping of Border collies for the VPS13B
deletion for dogs from the TNS pedigree, a set of
Australian Border collies unrelated to TNS affected










related† - 29 18
unrelated‡ - 40 220
Norway* 1 9 70
† ancestors and siblings of TNS affected dogs.
‡ Australian Border collie sample set collected prior to TNS work.
* sample set collected randomly to represent Border collie population of
Norway.
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TNS mutation. We have tested 5000 Border collies from
Europe, USA, UK, Australia, New Zealand and Japan,
1100 were carriers and 30 were affected. This sample set
of 5000 has a strong ascertainment bias towards dogs
with familial links to known carriers. To correct for this
ascertainment bias, we removed any samples where
either of the parents had been tested as carriers, leaving
2100 dogs. Allele frequencies ranged from 0.04 to 0.08
per country with an average of 0.064 from the sample
set of 2100 dogs (Additional file 1, Table S5).
A comparison between descriptions of Cohen syn-
drome patients in the literature and seven TNS affected
Border collies identified an overlap in disease character-
istics (Table 3). Features common to both Cohen syn-
drome and TNS include: typical facies; slender
extremities; infantile hypotonia; developmental delay;
and neutropenia. However, obesity and ophthalmic
abnormalities, which are other common Cohen syn-
drome clinical signs, were not found in Border collies
either because they are not present or could not be
examined (several affecteds are deceased and were
reported on posthumously). Mental retardation is a clin-
ical sign in Cohen syndrome that is difficult to assess in
dogs, but inability to learn simple commands was
reported by the breeder for three of the seven affecteds
dogs while some dogs were reported to be quick
learners.
To determine whether the mutation is causative rather
than linked to a non-coding VPS13B mutation or muta-
tion in another gene in the region we compared sequence
data from other species. High conservation of VPS13B is
observed at both the amino acid and DNA level across
mammalian species, for example human - dog homolo-
gies 90.4% for amino acids, 90.7% for mRNA; human -
mouse 87.3% for amino acids, 86.5% mRNA; dog - mouse
85.6% for amino acids, 84.8% mRNA. A multiple species
comparison using PhastCons from the UCSC genome
browser shows the most highly conserved regions to be
exons and transcription factor binding sites, which sug-
gests conservation in the regulation of VPS13B.
There is a large VPS13B transcript variant in human that
is not detected in mouse. The two largest putative tran-
scripts of VPS13B in the dog are variant 1 (XM_539102)
and variant 3 (XM_850840) which utilise an alternative
exon 27, referred to as exon 27b. To investigate the pre-
sence of these transcript variants in dog brain tissue, we
amplified cortex and cerebellum cDNA from three healthy
dogs by PCR using primers spanning the alternate exon
region (Additional file 1, Table S6). We found products of
684 bp corresponding to transcript variant 1 and 609 bp
corresponding to transcript variant 3 to be present in both
tissue types (Figure 2). The PCR fragment for transcript
variant 1 showed higher intensity on the gel suggesting
higher expression levels. A product of approximately
750 bp was also present on the gel at a lower concentra-
tion in cerebellum and was barely detectable in cortex. We
sequenced the PCR product mixture and found sequence
homozygosity up to the expected alternate exon site fol-
lowed by mixed sequence. The mixed sequence could be
resolved to the expected component sequences of the two
transcripts confirming that the bands on the gel were the
expected PCR products from the transcript variants.
Sequence from the 750 bp product was not detectable in
the sequence results from cortex or cerebellum, clear PCR
termination sites were identified at 589 bp and 664 bp
from the primer binding site.
We used comparative genomics to identify other spe-
cies capable of this alternative splicing by aligning refer-
ence genome sequences from NCBI and canine exons
27 and 27b. We observed that human, cow, horse,
mouse and rat all have an exon that is 67 bp in length
and highly similar sequence to exon 27b in dogs (Addi-
tional file 1, Figure S4). Human, horse and cow, but not
mouse or rat, have an exon 142 bp in length that is
highly similar in sequence to exon 27 in dogs. For this
exon, the mouse reference genome (C57BL/6J) had 80%
identity with a seven bp deletion compared to dog. The
rat (BN/SsNHsd) showed 80% identity for the first 59
bp of the sequence (Additional file 1, Figure S4), but a
271 bp deletion, relative to the mouse, disrupts the
sequence (Additional file 1, Figure S5).
Table 3 Comparison of clinical signs with percentages
between Cohen syndrome patients and seven TNS
affected Border collies
Clinical signs Cohen Syndrome (%)† TNS (%)
typical facies 81* 43
slender extremities 91 86
mental retardation 99 43
microcephaly 53 71
infantile hypotonia 86 71
developmental delay 81 86
delayed puberty 41 86
short stature 47 60‡




n/a - not available
* average for clinical signs: short philtrum, high narrow palate, prominent
nasal bridge and prominent central upper incisors
† Data summarised from Taban et al. [23] where the number of individuals for
each category varies depending on what has been reported in the literature
‡ out of five dogs as two died before reaching maturity
§ data summarised from Hennies et al. [24]; Kivitie-Kallio and Norio [25];
Chandler et al. [26]; Kolehmainen et al. [15]; Bugiani et al. [27]; Kivitie-Kallio et
al. [12]; and Seifert et al. [14].
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Discussion
The high frequency of the TNS deletion in the Border
collie population suggests that the mutation is much
older than the recent common ancestor of our affected
cases [7]. The mutation is present in Border collies in all
countries tested and in both the working dog and show
dog subgroups, which have been genetically isolated for
around 50 years. The widespread nature of the disease
indicates that the mutation was either already present in
the founder dogs used to establish the breed or origi-
nated very early in the breed. If the mutation predates
development of the breed it may exist in other collie
breeds, as does Collie Eye Anomaly [13]. The sample sets
collected from Norway and Australia prior to TNS
research represent an unbiased sample set giving the
most reliable disease allele proportion of 7-8%. The allele
proportions from other countries after correction for
ascertainment bias support the values obtained from
these two sample sets.
We have shown that TNS in Border collies is caused by
a mutation in the same gene that causes Cohen syn-
drome in humans, VPS13B. Over 80 mutations in human
VPS13B have been identified, all resulting in the charac-
teristic Cohen phenotype. The highly conserved nature of
VPS13B suggests that the mutation identified in the
canine form of the gene would cause similar clinical signs
to that observed in human. The strong similarity in clini-
cal signs between Cohen syndrome and TNS is support-
ing evidence that VPS13B is the TNS gene. We have
found no reports of mutations in this gene in other
organisms which makes TNS in the dog the first model
for Cohen syndrome.
Cohen syndrome is rare (~190 patients worldwide)
with a homogenous phenotype reported in Finnish
patients, who carry mainly the c.3348_3349delCT muta-
tion, and large variation in clinical signs in non-Finnish
patients who carry many different mutations [11,14].
Diagnosis of Cohen syndrome is based on the presence
of at least six of the following main clinical signs: devel-
opmental delay; microcephaly; typical Cohen syndrome
facial gestalt; truncal obesity with slender extremities;
overly sociable behaviour; joint hypermobility; high myo-
pia and/or retinal dystrophy; and neutropenia [15]. Bor-
der collies show developmental delay; microcephaly;
typical facial gestalt; slender extremities; and neutropenia,
which was enough overlap for us to suspect TNS was
homologous to Cohen syndrome.
The Cohen syndrome gene, VPS13B, is a potential trans-
membrane protein involved in vesicle-mediated transport
and sorting within the cell [11]. The gene is similar to
yeast Vps13 and is most highly conserved at the ends of
the protein which are similar to vacuolar protein sorting
domains [11]. Vps13 has undergone duplication events
early in vertebrate evolution resulting in four paralogous
copies VPS13A, B, C and D, which have diverged in func-
tion. The transcripts of each of the four genes typically
vary by a few amino acids in the middle of the sequence
and exhibit tissue specific expression. Each has one ubi-
quitous transcript and one transcript expressed in brain
[16]. Human VPS13B has four transcript variants, two
large transcripts utilising 62 exons each and two small
transcripts utilising eight and 18 exons.
The canine form of VPS13B is located at approximately
4.1 Mb on canine chromosome 13 (CFA13) and contains
63 exons with five putative transcript variants (NCBI Dog
Build V2.1). Seifert et al. [17] found that the full length
transcript variants showed the highest expression with
smaller transcripts barely detectable in both humans and
mice. This finding suggests that the smaller transcripts
are either from imperfect splicing or play a regulatory
role in VPS13B expression. It is also likely that the smal-
ler of the five putative transcripts listed for canine
VPS13B have similar expression and functions. The two
largest transcripts of VPS13B in humans utilise alternate
Figure 2 PCR product from cerebellum and cortex of three healthy dogs for primers spanning exon 25-28 of cDNA. Product 609 bp
and 684 bp is present corresponding to mRNA incorporating exons 27b or 27, respectively. Lanes one and eight contain a 100 bp ladder, lanes
two to four are cerebellum samples and five to seven are cortex samples from three healthy dogs.
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splicing to include either exon 28 (NM_017890) or 28b
(NM_152564) which are homologous to dog exons 27
and 27b, respectively. In humans, transcript NM_152564
is ubiquitous and transcript NM_017890 is expressed at
roughly 20% of the concentration compared to kidney,
placenta, small intestine, and lung, while in the brain and
retina both transcripts have roughly equal expression
[17].
Seifert et al. [17] have shown that mice lack a transcript
homologous to human NM_017890, and only the ubiqui-
tous transcript is detectable. We have shown that dogs
express both transcripts in the brain incorporating exons
27 or 27b. We also detected a weak product at around
750 bp which may correspond to the incorporation of
both exons 27 and 27b. The product was too weak to be
detected in mixed sequence in either cerebellum or cor-
tex. An mRNA incorporating both exons would change
the reading frame and considering the low levels of
expression is likely to be a splicing artefact.
We used comparative genomics to show that cow and
horse are also likely to express both transcripts. The
mouse and rat were found to have independent deletions
disrupting use of the exon homologous to canine exon
27. In the case of the mouse, utilising this exon would
change the reading frame and destroy protein function.
The deletion in the rat removes the 3’ half of the exon
destroying the splice signal. This shows that the alternate
transcript is not required in either mouse or rat.
Mental retardation observed in Cohen syndrome sug-
gests that VPS13B plays a role in brain development or
maintaining brain function in humans. Seifert et al. [17]
hypothesized that disruption to the transcript utilising
exon 28 may be responsible for the mental retardation
observed in Cohen syndrome. The lack of mutations dis-
covered in humans that involve sequence from either exon
28 or 28b make it difficult to test this hypothesis. Dogs
express both transcript variants in the brain and an
equivalent of mental retardation is observed in some TNS
affected dogs. This identifies dogs as a good model to test
the hypothesis that the human transcript utilising exon 28
may be responsible for mental retardation.
Conclusion
We have shown that TNS in Border collies is the result
of a mutation in VPS13B and that dogs, like humans,
express alternately spliced transcripts of VPS13B in the
brain. We have used comparative genomics to show that
other mammalian species are likely to express alter-
nately spliced transcripts in the brain, similar to human
and dog. Dogs affected with TNS are the first animal
model for Cohen syndrome and can be used to study
the development of the disease and the effect at the cel-
lular level of varying expression of VPS13B.
Methods
We extracted DNA from Border collie blood samples fol-
lowing a standard salting out method [18]. The pedigree
of affected dogs used in this study is published in Shear-
man and Wilton [7]. We designed primers for microsa-
tellite amplification and VPS13B sequencing (Additional
file 1, Tables S1 and S6) based on the canine genomic
sequence (NCBI Dog Build V2.1) using Primer3 [[19],
http://frodo.wi.mit.edu/primer3/.
We developed primers for four new microsatellites from
the VPS13B region using the reference canine sequence
(build 2.1) (Additional file 1, Table S1). We chose microsa-
tellites with a minimum of 20 repeat units of two to four
bp in the reference sequence and designed amplification
primers. We named microsatellites based on chromosome
number and location in units of 10 kb. C13.0390 (CFA13
at 390 × 104 bp) is approximately 197 kb before the tran-
scription start site of VPS13B, C13.0423 is in intron 16,
C13.0449 is in intron 24 and C13.0478 is in intron 43.
Additional microsatellites were used from dbSTS (NCBI)
(Additional file 1, Table S1). We used the universal prim-
ing method [20,21] to label PCR products which were
sized on an ABI3730 DNA analyser (Applied Biosystems)
with size standards GS500 and analysed using ABI Gene-
mapper software (Applied Biosystems). We performed
Linkage analysis using Superlink Online [22].
We designed primers to intron sequences to capture
the entire exon with intron-exon boundaries (Additional
file 1, Table S6). We performed sequencing using ABI
BigDye chemistry V3.1 (Applied Biosystems) and an
ABI3730 DNA analyser at the Ramaciotti Centre for
Gene Function Analysis. We aligned all exon sequences
to the reference dog genome and used Seqscape (Applied
Biosystems) to compare carriers and affecteds to control
Border collie sequences.
We designed primers flanking the deletion (Additional
file 1, Table S6) to develop a carrier test based on sizing
the PCR product on an ABI 3730 DNA Analyzer to
identify presence of the deletion.
The clinical sign analysis was based on a yes/no ques-
tionnaire, with a short description required for yes
answers, that was completed by owners of affected dogs.
The questions were based on clinical signs observed in
Cohen syndrome affected humans.
To detect presence of the alternately spliced transcripts
in dog we designed primers in exons 25 and 28 (Addi-
tional file 1, Table S6) to produce a product incorporating
alternately spliced products of exon 27 (XM_539102) or
27b (XM_850840). We expected the PCR product sizes
from transcripts XM_539102 and XM_850840 using these
primers to be 684 bp and 609 bp, respectively, based on
the reference genome sequence. We prepared the cortex
and cerebellum cDNA from three healthy dogs. We
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removed cortex tissue first and cerebellum tissue approxi-
mately 10 minutes later from dogs immediately after
euthanasia and placed the samples into liquid nitrogen.
We extracted RNA using the RNeasy Lipid Tissue Mini
Kit from Qiagen and prepared cDNA using poly-T pri-
mers and PCR. We performed PCR on the cDNA, ran the
PCR product on a 1% agarose gel and sequenced the PCR
mix using the above sequencing method.
Additional material
Additional file 1: Includes six supplementary figures and six
supplementary tables: Figure S1: Multipoint LOD scores for linkage to
TNS gene by microsatellites C13.0390, C13.0423, C13.0449, C13.0478 in
VPS13B region on CFA3. Figure S2: Genotypes at four microsatellite loci
near VPS13B in eight TNS affected border collies identified by Dog ID
number. Figure S3: Comparison of sequence electropherograms for an
affected, carrier and control Border collie showing four bp deletion in
exon 19 of VPS13B for bases 2894 to 2897 (transcript variant 1). Figure S4:
Sequence comparison of VPS13B exons 27 and 27b in human to dog,
horse, cow, rat and mouse showing high conservation for non-rodents.
Figure S5: Sequence comparison between mouse and rat of VPS13B
sequence homologous to exon 28 in human showing 271 bp deletion in
rat. Table S1: Microsatellite primers used for linkage analysis of candidate
genes. Table S2: Microsatellite allele sizes in 72 Border collies for the four
microsatellites in the VPS13B region. Table S3: Non-disease haplotypes for
the four microsatellites in the VPS13B region in 72 Border collies. Table
S4: Single nucleotide variations identified from sequencing genomic DNA
of VPS13B showing their genomic location, predicted effect on the
protein produced for transcript variant 1, dbSNP ID where available and
whether the SNP is in LD with TNS. Table S5: TNS Test results showing
allele proportions by country after correcting for ascertainment bias.
Table S6: Primers used to amplify exons from genomic DNA and from
cDNA variants, and sequence PCR products
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